Empagliflozin on Patients With Preserved Heart Failure

Sponsor
Damanhour University
Study ID
NCT07112274
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    Treatment group will receive empagliflozin 10 mg tablet once daily
  • Placebo Tablet — OTHER
    control group will receive placebo tablet.

Study Details

The proposed research in this application will investigate the effect of empagliflozin on cardiac remodeling in patients with heart failure with preserved ejection fraction.

Key Dates

Start date
Oct 1, 2022
Status verified
Nov 2025
Primary completion
Jun 30, 2025
Completion
Jul 30, 2025

Study Design

Enrollment
50 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin Group
    group (A) for empagliflozin (n=25),
  • Placebo Comparator: Placebo Group
    group (B) for placebo (n=25)

Primary Outcome Measure

NT-ProBNP [ Time Frame: 3 months ]

Related Studies